At Cambridge Enplas Life science Lab (C.E.L.L), we are working on innovative research in the life science market, developing a new model for immune drug efficacy testing; CELL is part of Enplas Europe Limited, a wholly owned subsidiary of Enplas Corporation, .
Enplas decided to take a step forward in the life Science market 17 years ago to answer the needs for microfluidic chips in the diagnostic market, by applying its core technology of plastic injection molding.
With the creation of CELL, we are looking to apply this expertise to answer the need of the pharmaceutical industry for a better early on model to mimic human immune system-tumour interaction, to optimise the drug development process, and reduce the failure rate in the later stage of the drug development process;
CELL as a lab is working on new method to test immuno-oncology drug efficacy with a microphysiological model that better represents the human tumour microenvironment s on a chip;
Enplas is also able to transform your ideas into a mass production chip using our expertise and global facilities.